
Sai Parenterals
CLOSEDIPO Date: 24 Mar - 27 Mar 2026
Listing Date: 2 Apr 2026
Price Range
Rs.372 - Rs.392
Issue Size
409 Cr
Min Investment
₹14,136
Lot Size
38 Shares
Schedule of Sai Parenterals
Issue open date
24 Mar 2026
Issue close date
27 Mar 2026
UPI mandate deadline
27 Mar 2026 (5 PM)
Allotment finalization
30 Mar 2026
Share credit
1 Apr 2026
Listing date
2 Apr 2026
Mandate end date
12 Apr 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 409 Cr |
| Fresh Issue | 285 Cr |
| Offer for Sale | 123.79 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 30 Mar 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 29 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 28 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 26 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 25 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 23 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 22 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 21 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 20 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 19 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 18 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
| 17 Mar 2026 | ₹392 | ₹0 | ₹392 (0%) |
Performance Sai Parenterals
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.372 - Rs.392 | .... | .... | .... |
About Sai Parenterals
Sai Parenteral’s Limited is a pharmaceutical formulations company engaged in the research, development, and manufacturing of pharmaceutical products. The company operates in two main segments: branded generic formulations and contract development and manufacturing organisation (CDMO) services for domestic and international markets. Its product portfolio covers multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins and supplements, analgesics, and dermatology. The company manufactures products in several dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenterals supplies its branded generic formulations to customers, including government agencies, pharmaceutical companies, hospitals, and distributors in India, and also exports products to markets such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company operates five manufacturing facilities in India, four of which are located in Hyderabad, Telangana, while another facility owned by its subsidiary Revat Laboratories is located in Ongole, Andhra Pradesh. These facilities manufacture pharmaceutical formulations in compliance with applicable regulatory standards.
| Founded in | 2001 |
| Managing director | Mr Anil Kumar Karusala |
| Parent organization |
Financial Overview
Strengths
- Diversified pharma portfolio across branded generics and CDMO services
- Strong capabilities in sterile injectable manufacturing
- Presence across multiple therapeutic areas and dosage forms
- Promoter-led management with a long operating track record
- Multiple manufacturing facilities supported by in-house R&D
Risks
- High revenue dependence on injectable formulations
- Manufacturing facilities are concentrated in limited geographies
- Exposure to stringent regulatory inspections and compliance risks
- Dependence on third-party suppliers for key raw materials
- Customer concentration may affect revenue stability
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 1.71 |
| Non-Institutional Investors (NIIs) | 2.36 |
| Retail Individual Investors (RIIs) | 0.12 |
| Employee | N/A |
| Total | 1.05 |